Sendai virus (SeV) vectors are able to infect a diverse range of cells. They have a high affinity for epithelial cells in the respiratory tract, which provides advantageous properties for intranasal inoculation. Vaccination of the respiratory tract, the main route of infection for Coronavirus (COVID-19), can strongly induce mucosal immunity, which is difficult to induce through injected vaccines, in addition to systemic immunity in a manner similar to innate immunity. A SeV vector vaccine carrying part of the SARS-CoV-2 spike-protein gene showed high immunogenicity in pharmacological studies using intranasally inoculated rodents and is a promising next-generation vaccine.
No takes yet. Share an insight, caveat, or question.
Shimazaki et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: